Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13391635 | 0.78 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL10785234 | 0.78 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL9441831 | 0.78 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL2782005 | 0.76 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL9492996 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| Bromide SCHEMBL493074 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL14315744 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| Bromide SCHEMBL8602057 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| Iodide SCHEMBL491999 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| Hydrochloric Acid SCHEMBL493348 | 0.74 | TDP1 (0.41) | CYP3A4TDP1ESR1ESR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716508-B2 | Method for preparing a metal catalyst | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-05-06 | — | — | US | disclosed |
| US-20120046479-A1 | METHOD FOR PREPARING A METAL CATALYST | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046479-A1 | METHOD FOR PREPARING A METAL CATALYST | INPP5B, DNPEP, AOC1 | CYP3A4 2744/4885TDP1 1106/4885ESR1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.